TheScreener
Fundamental and technical screening for 1,000 listed companies.
Use ⌘K to search stocks, screens, and features instantly.
Advanced Enzyme Tech Ltd.
ADVENZYMESSmall CapNSEBSE
Biotechnology & Drugs · Healthcare
₹294.10down 5.70down 1.90 percentas of 31 Aug 2026
Book value ₹144.17Div yield 0.46%
Key metrics
- Market Cap
- 3,282.91 ₹ cr
- P/E
- 19.91 x
- P/B
- 2.04 x
- ROE
- 10.26%
- ROCE
- 11.59%
- Debt to Equity
- 0.02 x
- Net Margin
- 22.62%
- Dividend Yield
- 0.46%
- Revenue Growth (YoY)
- 2.09%
Observations
Mechanical observations generated from stored data, not analysis or opinion. Each one names the threshold that produced it — the ROCE check below uses 20%, a fixed default rather than a value tailored to this company.
- ROCE below 20% in each of the last 3 financial years (2023-2024, 2024-2025, 2025-2026).
- Revenue grew year-on-year in each of the last 3 years.
- Net margin declined year-on-year in 1 of the last 3 years.
- Promoter holding 43.2% (pledge data not available).
- Debt-to-equity 0.02 — below the Healthcare median of 0.32.
ADVENZYMES
₹294.10down 1.90 percent
EOD Synced: 31 Aug 2026 18:30 ISTOverview & Live Price Chart
Executive Investment Verdict & Quality Synthesis
Autonomous V2Multi-dimensional quantitative synthesis across capital efficiency, forensic accounting, intrinsic valuation, and ownership governance.
Factual Quantitative Consensus
1. Capital Efficiency & MoatModerate Return
11.59%ROCE
ROE: 10.26%·P/B: 2.04x
2. Forensic Health & SolvencyPiotroski 8/9 · Strong Health
8/9Piotroski Score
Altman: 15.2 (Safe Zone)
3. Valuation & DCF Spread-45.4% Valuation Premium
₹160DCF Fair Value
CMP: ₹294.1
4. Ownership & GovernanceClean Promoter Holding
43.24%Promoter Stake
Pledged: 0.0%·Inst: 28.52%
Institutional Factor Scores
QVGM Factor Grade Matrix
Institutional Multi-Factor Profile (QVGM)
Composite 0–100 percentile ranks normalized across all 500 universe constituents
Rank #16 of 35 in Biotechnology & DrugsQVGM 51/100
Quality (Q)53
ROE, ROCE, Margins & Cash Conversion
Value (V)67
P/E, P/B, EV/EBITDA vs Sector Benchmarks
Growth (G)50
3Y Sales & EPS Compounded Growth
Momentum (M)30
Relative Strength & Trend Position
TheScreener Radar™ 5-Pillar Quantitative Scorecard
Holistic quantitative radar evaluating fundamental quality, valuation multiples, balance sheet health, growth, and price momentum
Sector Rank:Rank #16 of 35 in Biotechnology & Drugs
Valuation
Moderate67/100
P/E Ratio:19.91x
P/B Ratio:2.04x
Dividend Yield:0.46%
P/E, P/B, EV/EBITDA & Dividend Yield relative to 5Y medians and sector
Growth
Moderate50/100
3Y Sales CAGR:—
3Y PAT CAGR:—
Quarterly YoY:+12.4%
3-Year Compounded Sales & Net Profit Growth trajectory
Profitability
Moderate53/100
ROE:10.3%
ROCE:11.6%
OPM %:—
Return on Equity (ROE), ROCE & Operating Margin efficiency
Solvency & Health
Strong89/100
Piotroski F-Score:8/9
Altman Z-Score:15.21
Debt / Equity:0.00
Balance Sheet strength, Altman Z-Score & Piotroski F-Score checklist
Momentum
Weak30/100
1Y Return:—
RSI (14):54.2
From 52W High:—
1-Year Relative Strength vs NIFTY 500, RSI-14 & 52W High distance
Quantitative Drivers & Growth Analysis
52-week corridor, deep valuation multiples, compounded CAGR trajectory, and institutional flow shifts
52-Week Low₹255.30
From 52W High-24.99%
52-Week High₹392.10
Valuation MultiplesCash Flow & Yield
PEG Ratio1.48
Earnings Yield4.87%
Price / FCF31.40
FCF Yield3.18%
Payout Ratio9.42%
Net-Net Ratio25.86
Solvency & SafetyPiotroski & Altman
Piotroski F-Score8/9
Altman Z-Score15.21
Graham Number₹215.60
1Y Flow & Margin ShiftsTrailing 12M
FII Stake:▲ +1.20%
DII Stake:▼ 0.11%
OPM Margin:▲ +2.11%
Net Margin:▲ +2.04%
Compounded Annual Growth Rate (CAGR Matrix)
Historical Fundamental Trajectory| Metric | QoQ Shift | YoY Shift | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|
| Revenue Growth | ▼ 6.68% | ▲ +2.09% | 17.09% | 11.32% | 8.24% |
| Net Profit Growth | ▼ 13.66% | ▼ 7.11% | 28.68% | 16.89% | 2.91% |
| EPS Growth | ▼ 13.58% | ▼ 7.28% | 22.58% | 13.46% | 2.33% |
Intrinsic Valuation Models & DCF Sensitivity
Institutional DCF & Intrinsic Valuation Studio — ADVENZYMES
2-Stage Discounted Cash Flow, Reverse DCF Implied Growth, and Benjamin Graham & Peter Lynch valuation benchmarks.
DCF Intrinsic Fair Value
₹165.8
Verdict:Overvalued (-43.6%)
Benjamin Graham Number
₹217.7
-26% vs CMPPeter Lynch Fair Value
₹192.9
-34.4% vs CMPReverse DCF Implied Growth
25.6% CAGR
Aggressive Expectations (Priced for Perfection)Valuation Spectrum PositioningCMP: ₹294.1
₹0 (Distress)CMP: ₹294DCF: ₹166Graham: ₹218
Scenario Calibration & Sensitivity Levers
Tune Discount Rate (WACC), 5-Year Growth, and Terminal Value to model bear, base, and bull cases.
Discount Rate (WACC)11.5%
Cost of Capital Hurdle
5-Year FCF Growth CAGR8.4%
Assumed stage-1 cash flow expansionTerminal Growth Rate4.5%
Long-term perpetual GDP growth rate5-Year Projected Cash Flow Schedule (₹ Cr)
| Projection Period | Growth Rate | Projected FCF | Discount Factor | Present Value |
|---|---|---|---|---|
| Year 1 | 8.4% | ₹113 | 0.8969 | ₹102 |
| Year 2 | 8.4% | ₹123 | 0.8044 | ₹99 |
| Year 3 | 8.4% | ₹133 | 0.7214 | ₹96 |
| Year 4 | 8.4% | ₹144 | 0.6470 | ₹93 |
| Year 5 | 8.4% | ₹156 | 0.5803 | ₹91 |
2D Sensitivity Matrix (WACC vs Terminal Growth Rate)
Click any cell to apply WACC & terminal growth scenario. Values in ₹ / share.| WACC \ g(Terminal) | 3.0% | 4.0% | 4.5% | 5.0% | 6.0% |
|---|---|---|---|---|---|
| 10.0% | ₹174 -41% | ₹197 -33% | ₹211 -28% | ₹229 -22% | ₹276 -6% |
| 11.0% | ₹152 -48% | ₹169 -43% | ₹179 -39% | ₹190 -35% | ₹221 -25% |
| 11.5% | ₹143 -51% | ₹157 -47% | ₹166 -44% | ₹176 -40% | ₹201 -32% |
| 12.0% | ₹135 -54% | ₹147 -50% | ₹155 -47% | ₹163 -45% | ₹184 -37% |
| 13.0% | ₹121 -59% | ₹131 -56% | ₹136 -54% | ₹143 -51% | ₹158 -46% |
Discounted cash flow (DCF) and valuation models are quantitative projections based on user-supplied assumptions — not a forecast, not a guarantee of future performance, and not SEBI-registered investment advice. Actual financial performance and stock price movements may differ materially.
New to intrinsic valuation models? Learn how Discounted Cash Flow and Terminal Growth rates work.Read DCF Academy Guide →
Valuation history
P/E19.91current
ReportedComputed, approximate
P/B2.04current
ReportedComputed, approximate
The dashed line is computed from historical close price divided by the most recently reported annual EPS or book value — not IndianAPI's own figure, which only ever gives a single current reading with no history behind it. Real results are typically disclosed several weeks after the fiscal year ends, so a computed point right around a year transition can lag what the market actually knew that day. The solid line is the real reported figure.
EV/EBITDA is not shown — there is no verified source for it in our data feed, and estimating it would misrepresent an estimate as a reported figure.
| Date | P/E | P/B |
|---|---|---|
| 31 Aug 2026 | 19.91 | 2.04 |
Analyst Consensus, Price Targets & Forecasts
Analyst Consensus & Recommendations
Aggregated institutional equity research ratings · 31 Aug 2026
Buy(2.00 / 5)
Strong Buy:0
Buy:1
Hold:0
Sell:0
Strong Sell:0
Coverage: 1 contributing analystsScale: 1 (Strong Buy) – 5 (Strong Sell)
Ratings shown are third-party analyst estimates compiled from institutional brokers. They do not constitute investment advice.
Risk Profile & Volatility
Statistical return volatility classification · 31 Aug 2026
Balanced risk
Low RiskModerate RiskHigh Risk
Annualised Standard Deviation:41.21%
Analyst Price Targets
12-month forward price consensus · 31 Aug 2026
Upside: +25.81%
Mean Target₹370.00vs CMP ₹294.10
High Target₹370.00+25.8% max upside
Low Target₹370.0025.8% downside
Median Target₹370.001 estimate
Price targets are third-party analyst estimates compiled from institutional brokers. They do not constitute investment advice.
Forward Financial Forecasts & Consensus Estimates
Institutional broker consensus estimates and forward earnings trajectory
FY2024EConsensus
Mean Estimate
₹3.88
Low:—
High:—
FY2024EConsensus
Mean Estimate
₹3.08
Low:—
High:—
FY2024EConsensus
Mean Estimate
₹3.74
Low:—
High:—
FY2024EConsensus
Mean Estimate
₹2.58
Low:—
High:—
FY2025E1 Analysts
Mean Estimate
₹3.36
Low:—
High:—
FY2025EConsensus
Mean Estimate
—
Low:—
High:—
FY2025E1 Analysts
Mean Estimate
₹2.37
Low:—
High:—
FY2025EConsensus
Mean Estimate
—
Low:—
High:—
FY2026EConsensus
Mean Estimate
—
Low:—
High:—
FY2026EConsensus
Mean Estimate
—
Low:—
High:—
FY2026EConsensus
Mean Estimate
—
Low:—
High:—
FY2026EConsensus
Mean Estimate
—
Low:—
High:—
FY2027EConsensus
Mean Estimate
—
Low:—
High:—
| Period / Fiscal Year | Consensus Mean | Bull Case (High) | Bear Case (Low) | Brokers |
|---|---|---|---|---|
| FY2024 Forecast | ₹3.88 | — | — | — |
| FY2024 Forecast | ₹3.08 | — | — | — |
| FY2024 Forecast | ₹3.74 | — | — | — |
| FY2024 Forecast | ₹2.58 | — | — | — |
| FY2025 Forecast | ₹3.36 | — | — | 1 |
| FY2025 Forecast | — | — | — | — |
| FY2025 Forecast | ₹2.37 | — | — | 1 |
| FY2025 Forecast | — | — | — | — |
| FY2026 Forecast | — | — | — | — |
| FY2026 Forecast | — | — | — | — |
| FY2026 Forecast | — | — | — | — |
| FY2026 Forecast | — | — | — | — |
| FY2027 Forecast | — | — | — | — |
Third-party broker forecasts compiled from institutional research houses, not IndiScreener's proprietary estimates. Provided strictly for analytical benchmarking and does not constitute investment advice.
Forensic Accounting Audit & Solvency Risk
Accounting Health & Governance Quality Radar
Algorithmic accounting analysis across balance sheet solvency, cash conversion efficiency, and ownership stability.
Clean Governance & Solvency
Financial Strengths & Catalysts
4 Factors- •Company is virtually debt-free with a Debt-to-Equity ratio of 0.02x.
- •Company has reduced borrowings by 18.7% over the last fiscal year.
- •Strong cash generation: Operating Cash Flow is 92.9% of reported Net Profit.
- •High institutional backing: FIIs & DIIs hold a combined 28.5%.
Risk Factors & Watchouts
0 WatchoutsClean profile: No major debt, leverage, or working capital red flags detected.
Forensic Accounting & Health Audit
Piotroski F-Score, Altman Z-Score Distress Model & Beneish Earnings Manipulation Checks
Piotroski F-Score8 / 9
● Strong (High Quality)
Altman Z-Score15.21
● Safe Zone
Negligible risk of financial distress over the next 2 years.
Beneish M-Score-2.51
● Low Risk (Clean Accounting)
Cash flows closely match reported earnings with conservative accruals.
Learn how Piotroski F-Score (9 criteria) and Altman Z-Score detect earnings manipulation and bankruptcy risk.Read Forensic Guide →
10-Year Financial Statements & DuPont ROE
Financial Statements
consolidated · amounts in ₹ Crores
Accounting Flow:
Wall Street Cash Flow & Free Cash Flow (FCF) Cascade
FY26 (2025-2026)3-Stage institutional flow from reported earnings to owner Free Cash Flow and capital allocation
FCF Conversion Rate (FCF / PAT)
62.0%Low Cash Conversion
Measures how much reported accounting profit turns into real liquid cash.
Free Cash Flow Margin
14.0%of Gross Revenue
Liquid cash retained per ₹100 of top-line revenue generated.
CapEx Reinvestment Rate
33.3%of Operating Cash
Portion of operating cash reinvested in future capacity and maintenance.
Reported Net Profit (PAT)₹169 CrInflow
169
+ D&A Non-Cash Charge₹40 CrAdd-back
40
Working Capital Adjustment-₹52 Cr- Tied Up
52
= Operating Cash Flow (CFO)₹157 CrOperating Cash
157
- Capital Expenditures (CapEx)-₹52 CrReinvestment
52
= Free Cash Flow (FCF)₹105 CrFree Cash Flow
105
- Dividends & Debt Repayment-₹37 CrCapital Return
37
= Net Change in Cash₹68 CrNet Balance
68
Multi-Year Historical FCF vs Reported PAT Trajectory:
Free Cash Flow (FCF) Reported Net Profit (PAT)
| Metric | 2018-201931 Mar 2019 | 2019-202031 Mar 2020 | 2020-202131 Mar 2021 | 2021-202231 Mar 2022 | 2022-202331 Mar 2023 | 2023-202431 Mar 2024 | 2024-202531 Mar 2025 | 2025-202631 Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹419.59 | ₹443.99 | ₹501.84 | ₹529.38 | ₹540.64 | ₹623.87 | ₹636.91 | ₹745.76 |
| Operating profit | ₹160.86 | ₹176.88 | ₹207.84 | ₹166.48 | ₹120.93 | ₹154.41 | ₹157.92 | ₹200.66 |
| OPM | 38.34% | 39.84% | 41.42% | 31.45% | 22.37% | 24.75% | 24.79% | 26.91% |
| Net profit | ₹111.06 | ₹129.29 | ₹146.20 | ₹119.58 | ₹105.64 | ₹133.31 | ₹131.12 | ₹168.72 |
| EPS | 9.94 | 11.57 | 12.77 | 10.62 | 9.81 | 12.92 | 11.69 | 14.33 |
| Net margin | 26.47% | 29.12% | 29.13% | 22.59% | 19.54% | 21.37% | 20.59% | 22.62% |
| ROE | 16.36% | 15.40% | 15.06% | 10.90% | 8.47% | 9.98% | 9.15% | 10.26% |
| ROCE | 21.56% | 19.25% | 19.09% | 13.79% | 9.00% | 10.80% | 10.36% | 11.59% |
| Debt / equity | 0.05 | 0.04 | 0.03 | 0.03 | 0.03 | 0.04 | 0.03 | 0.02 |
Compounded growth (CAGR)
| Metric | 1Y | 3Y | 5Y |
|---|---|---|---|
| Revenue | 17.09% | 11.32% | 8.24% |
| Net profit | 28.68% | 16.89% | 2.91% |
| EPS | 22.58% | 13.46% | 2.33% |
Each column only appears when 8 real reported years actually support it — never extrapolated from fewer.
Balance sheet
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Total assets | ₹811.09 | ₹978.61 | ₹1,156.17 | ₹1,267.61 | ₹1,421.85 | ₹1,535.46 | ₹1,621.35 | ₹1,838.76 |
| Total liabilities | ₹132.25 | ₹138.95 | ₹185.23 | ₹170.26 | ₹175.16 | ₹199.10 | ₹188.25 | ₹194.57 |
| Total equity | ₹678.85 | ₹839.65 | ₹970.94 | ₹1,097.35 | ₹1,246.69 | ₹1,336.37 | ₹1,433.10 | ₹1,644.20 |
| Total debt | ₹32.61 | ₹31.89 | ₹27.79 | ₹34.56 | ₹33.50 | ₹47.31 | ₹39.35 | ₹32.01 |
| Cash | — | ₹50.17 | ₹118.05 | ₹185.36 | ₹60.05 | ₹42.00 | ₹27.48 | ₹52.17 |
| Current assets | ₹282.06 | ₹375.57 | ₹516.01 | ₹604.44 | ₹722.11 | ₹809.74 | ₹879.87 | ₹1,043.57 |
| Current liabilities | ₹65.12 | ₹59.55 | ₹67.56 | ₹60.42 | ₹77.57 | ₹106.36 | ₹96.76 | ₹106.72 |
| Inventory | ₹77.24 | ₹81.59 | ₹95.85 | ₹123.93 | ₹128.13 | ₹152.44 | ₹159.10 | ₹179.52 |
| Receivables | ₹58.73 | ₹74.74 | ₹86.43 | ₹88.26 | ₹100.56 | ₹99.25 | ₹115.81 | ₹145.54 |
| Payables | ₹9.68 | ₹9.64 | ₹15.22 | ₹17.90 | ₹24.22 | ₹15.76 | ₹17.20 | ₹39.96 |
| Net PP&E | ₹166.52 | ₹214.33 | ₹251.03 | ₹271.81 | ₹288.82 | ₹307.27 | ₹314.63 | ₹327.00 |
| Retained earnings | ₹545.12 | ₹665.06 | ₹804.72 | ₹912.31 | ₹1,006.83 | ₹1,087.07 | ₹1,162.58 | ₹1,278.03 |
Cash flow
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | ₹128.57 | ₹140.90 | ₹163.49 | ₹122.29 | ₹140.38 | ₹141.37 | ₹142.50 | ₹156.78 |
| Capital expenditure | ₹-12.39 | ₹-50.65 | ₹-19.45 | ₹-28.12 | ₹-38.11 | ₹-42.31 | ₹-33.81 | ₹-52.23 |
| Free cash flow | ₹116.18 | ₹90.25 | ₹144.04 | ₹94.17 | ₹102.27 | ₹99.06 | ₹108.69 | ₹104.55 |
| OCF / net profit | 1.16 | 1.09 | 1.12 | 1.02 | 1.33 | 1.06 | 1.09 | 0.93 |
| FCF / Capex intensity | 2.95 | 11.41 | 3.88 | 5.31 | 7.05 | 6.78 | 5.31 | 7.00 |
Income statement detail
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Gross profit | ₹315.54 | ₹333.44 | ₹368.65 | ₹380.49 | ₹360.20 | ₹424.12 | ₹434.67 | ₹495.16 |
| Cost of revenue | ₹104.05 | ₹110.55 | ₹133.19 | ₹148.89 | ₹180.44 | ₹199.75 | ₹202.24 | ₹250.59 |
| EBITDA | ₹181.98 | ₹202.66 | ₹236.25 | ₹201.46 | ₹155.96 | ₹189.65 | ₹194.48 | ₹240.75 |
| Income before tax | ₹161.96 | ₹179.16 | ₹210.37 | ₹171.06 | ₹140.39 | ₹187.82 | ₹187.36 | ₹232.54 |
| Interest expense | ₹3.54 | ₹1.84 | ₹1.17 | ₹1.15 | ₹2.72 | — | — | — |
| Tax expense | ₹46.06 | ₹46.11 | ₹58.91 | ₹47.26 | ₹36.52 | ₹50.87 | ₹53.39 | ₹58.93 |
| D&A | ₹21.12 | ₹25.78 | ₹28.41 | ₹34.98 | ₹35.03 | ₹35.24 | ₹36.56 | ₹40.09 |
| EBITDA margin | 43.37% | 45.65% | 47.08% | 38.06% | 28.85% | 30.40% | 30.53% | 32.28% |
Financial ratios
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Current ratio | 4.33 | 6.31 | 7.64 | 10.00 | 9.31 | 7.61 | 9.09 | 9.78 |
| Quick ratio | 3.15 | 4.94 | 6.22 | 7.95 | 7.66 | 6.18 | 7.45 | 8.10 |
| Interest coverage | 45.44 | 96.13 | 177.64 | 144.77 | 44.46 | — | — | — |
| Inventory days | 270.95 | 269.38 | 262.67 | 303.81 | 259.19 | 278.55 | 287.14 | 261.48 |
| Receivable days | 51.09 | 61.44 | 62.86 | 60.85 | 67.89 | 58.07 | 66.37 | 71.23 |
| Payable days | 33.96 | 31.83 | 41.71 | 43.88 | 48.99 | 28.80 | 31.04 | 58.20 |
| Cash conversion cycle | 288.08 | 299.00 | 283.82 | 320.78 | 278.08 | 307.82 | 322.47 | 274.51 |
| Working capital days | — | — | — | — | — | — | — | — |
| Fixed asset turnover | 2.52 | 2.07 | 2.00 | 1.95 | 1.87 | 2.03 | 2.02 | 2.28 |
| ROA | 13.69% | 13.21% | 12.65% | 9.43% | 7.43% | 8.68% | 8.09% | 9.18% |
| ROIC | — | 15.99% | 16.99% | 12.73% | 7.33% | 8.39% | 7.81% | 9.22% |
| Gross margin | 75.20% | 75.10% | 73.46% | 71.87% | 66.62% | 67.98% | 68.25% | 66.40% |
DuPont 3-Stage ROE Factor Decomposition
Deconstructing Return on Equity into Profitability, Asset Efficiency, and Financial Leverage
High Quality Moat (Margin Driven, Low Debt Risk)FY2025-2026
Net marginProfitability
22.62%
Net Profit generated per ₹100 of revenue (Profitability)
×
Asset turnoverEfficiency
0.41
Revenue generated per ₹1 of total assets (Capital Efficiency)
×
Equity multiplierLeverage
1.12
Total assets supported per ₹1 of shareholder equity (Leverage)
=
Implied DuPont ROEFinal Output
10.26%
Reported: 10.26%
Explore the 3-Stage DuPont Formula: Net Margin × Asset Turnover × Leverage Multiplier.Read DuPont Guide →
Corporate Actions, Dividends & Capital Changes
Chronological Corporate Actions Registry
Historical stock splits, bonus shares, rights issues, and corporate schemes
| Year | Execution Date | Action Type | Ratio / Term |
|---|---|---|---|
| 2026 | 24 Jul 2026 | dividend | 67% |
| 2025 | 23 Jul 2025 | dividend | 60% |
| 17 May 2025 | dividend | 200% | |
| 2024 | 18 Jul 2024 | dividend | 55% |
| 18 May 2024 | dividend | 200% | |
| 2023 | 05 Aug 2023 | dividend | 50% |
| 20 May 2023 | dividend | 200% | |
| 2022 | 12 Aug 2022 | dividend | 50% |
| 2021 | 01 Sept 2021 | dividend | 45% |
| 2020 | 11 Jul 2020 | dividend | 30% |
| 2019 | 03 Aug 2019 | dividend | 30% |
| 03 Aug 2019 | dividend | 30% | |
| 2018 | 08 Sept 2018 | dividend | 25% |
| 08 Sept 2018 | dividend | 25% | |
| 2017 | 06 Sept 2017 | dividend | 20% |
| 26 May 2017 | split | 2:10 |
Dividend Intelligence & Capital Return History
Historical cash payout track record across 9 dividend distributions
Latest Year DPS:₹1.35
Yield on CMP:0.46%
3Y Dividend CAGR:-35.4%
Annual Dividend Payout Progression (Per Share)Total Cumulative DPS: ₹18.55
₹1.4
2026
₹5.2
2025
₹5.1
2024
₹5.0
2023
₹1.0
2022
₹0.9
2021
| Ex-Date | Amount (Per Share) | Dividend Type |
|---|---|---|
| 24 Jul 2026 | ₹1.35 | Final |
| 23 Jul 2025 | ₹1.20 | Final |
| 16 May 2025 | ₹4.00 | Interim |
| 18 Jul 2024 | ₹1.10 | Final |
| 17 May 2024 | ₹4.00 | Interim |
| 04 Aug 2023 | ₹1.00 | Final |
| 19 May 2023 | ₹4.00 | Interim |
| 11 Aug 2022 | ₹1.00 | Final |
| 31 Aug 2021 | ₹0.90 | Final |
Industry Peer Group & Valuation Spread
Compare valuation multiples and market cap relative to sector competitors
HealthcareCompare Peers in Studio
Market Cap3,282.91 ₹ cr
Beats 0% of 65 industry peers · median 26,449.73 ₹ cr
P/E19.91 x
Beats 5% of 60 industry peers · median 51.05 x
P/B2.04 x
Beats 5% of 62 industry peers · median 6.18 x
ROE10.26%
Beats 34% of 65 industry peers · median 14.40%
ROCE11.59%
Beats 32% of 65 industry peers · median 16.66%
Debt to Equity0.02 x
Beats 6% of 65 industry peers · median 0.32 x
Net Margin22.62%
Beats 89% of 65 industry peers · median 13.15%
Dividend Yield0.46%
Beats 53% of 53 industry peers · median 0.42%
Revenue Growth (YoY)2.09%
Beats 11% of 64 industry peers · median 19.32%
| Company | Market Cap ▼ | P/E | P/B |
|---|---|---|---|
Sun Pharmaceutical Industries Ltd.SUNPHARMA | ₹4.61 L | 41.52 | 5.51 |
Torrent Pharmaceuticals Ltd.TORNTPHARM | ₹1.88 L | 79.00 | 20.38 |
Apollo Hospitals Enterprise Ltd.APOLLOHOSP | ₹1.27 L | 65.49 | 13.41 |
Zydus Lifesciences Ltd.ZYDUSLIFE | ₹1.16 L | 23.78 | 4.42 |
Cipla Ltd.CIPLA | ₹1.14 L | 29.66 | 3.34 |
Peers are chosen strictly by industry classification. A classification doesn't always describe what a company actually competes in, but gives an objective starting point across the universe.
Regulatory Filings & Market Intelligence
Corporate Document & Filings Vault
No statutory exchange announcements or PDF filings have been recorded for ADVENZYMES yet.
News
- IndianAPIAdvanced Enzyme Technologies share: Biotechnology stock jumps 9% despite stock market sell-off
Advanced Enzyme Technologies share: Advanced Enzyme Technologies share price rose 12% on Friday, marking a two-day increase driven by higher trading volumes. The stock reached an intraday high of ₹362.85, with significant institutional activity, according to experts.
- IndianAPIBuy or sell: Vaishali Parekh recommends three stocks to buy today — 26 August 2025
Buy or sell: Vaishali Parekh recommends three stocks to buy today — Gufic BioSciences, IRB Infrastructure, and Advanced Enzyme Technologies
For informational and educational purposes only. Not investment advice. Data may be delayed or incomplete. Consult a SEBI-registered investment adviser before making investment decisions.